Current status of antiangiogenic therapies for glioblastomas

RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).

(2017) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).

(2017) Erik P. Sulman et al.   JOURNAL OF CLINICAL ONCOLOGY

A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma

(2017) David A. Reardon et al.   Journal of the National Comprehensive Cancer Network

Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth

(2013) Lin Cheng et al.   CELL

Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance

(2013) A. Jahangiri et al.   CLINICAL CANCER RESEARCH

Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy

(2013) Olivier L. Chinot et al.   Current Neurology and Neuroscience Reports

Denosumab Treatment of Metastatic Giant-Cell Tumor of Bone in a 10-Year-Old Girl

(2013) Nicole A. Karras et al.   JOURNAL OF CLINICAL ONCOLOGY

Harnessing Technology to Improve Clinical Trials: Study of Real-Time Informatics to Collect Data, Toxicities, Image Response Assessments, and Patient-Reported Outcomes in a Phase II Clinical Trial

(2013) M. Catherine Pietanza et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma

(2013) C. Lu-Emerson et al.   NEURO-ONCOLOGY

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

(2012) D A Reardon et al.   BRITISH JOURNAL OF CANCER

VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex

(2012) Kan V. Lu et al.   CANCER CELL

Antiangiogenic Therapy for Glioblastoma

(2012) Elizabeth R. Gerstner et al.   CANCER JOURNAL

Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma

(2012) Y.-L. Hu et al.   CANCER RESEARCH

A novel treatment for glioblastoma: integrin inhibition

(2012) Marc C Chamberlain et al.   Expert Review of Neurotherapeutics

Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies

(2012) Justin N. Bottsford-Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth

(2012) Petra Hamerlik et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A phase I/II trial of vandetanib for patients with recurrent malignant glioma

(2012) T. N. Kreisl et al.   NEURO-ONCOLOGY

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype

(2012) Y. Piao et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009

(2012) T. A. Dolecek et al.   NEURO-ONCOLOGY

Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status

(2011) D.-S. Kong et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

(2011) L.C. Hygino da Cruz et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

(2011) John F. de Groot et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

(2011) J. S. Wefel et al.   NEURO-ONCOLOGY

Hypoxia Potentiates Glioma-Mediated Immunosuppression

(2011) Jun Wei et al.   PLoS One

Reversible modulations of neuronal plasticity by VEGF

(2011) T. Licht et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

(2010) John D. Hainsworth et al.   CANCER

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice

(2010) Mitomu Kioi et al.   JOURNAL OF CLINICAL INVESTIGATION

Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma

(2010) Christina Tsien et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53

(2010) Hyun-Cheol Kang et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

(2010) B. Neyns et al.   JOURNAL OF NEURO-ONCOLOGY

Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1

(2009) C. Folkins et al.   CANCER RESEARCH

Hypoxia-induced autophagy: cell death or cell survival?

(2009) Nathalie M Mazure et al.   CURRENT OPINION IN CELL BIOLOGY

Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice

(2009) Walid S. Kamoun et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression

(2009) Elizabeth R. Gerstner et al.   JOURNAL OF NEURO-ONCOLOGY

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients

(2008) Lin-Fang Wang et al.   BMC CANCER

HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion

(2008) Rose Du et al.   CANCER CELL

Flt-1 Signaling in Macrophages Promotes Glioma Growth In vivo

(2008) M. Kerber et al.   CANCER RESEARCH

Tumor Escape from Endogenous, Extracellular Matrix-Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors

(2008) N. T. Fernando et al.   CLINICAL CANCER RESEARCH

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel anti-angiogenic therapies for malignant gliomas

(2008) Andrew D Norden et al.   LANCET NEUROLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE